RecruitingPhase 1Phase 2NCT06090227

AMPK-activation by Metformin in FSGS: AMP-FSGS

Sponsor

Yale University

Enrollment

30 participants

Start Date

Dec 14, 2023

Study Type

INTERVENTIONAL

Conditions

Focal Segmental Glomerulosclerosis

Summary

The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metformin + Standard of Care and Placebo + Standard of Care for people with focal segmental glomerulosclerosis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin + Standard of Care

Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.

OTHERPlacebo + Standard of Care

Administration of daily placebo tablets with standard of care for 6 months.

Locations(2)

Yale New Haven Hospital

New Haven, Connecticut, United States

Mount Sinai Hospital

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06090227

Related Trials

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

NCT066648141 location

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083296 locations

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT0650070271 locations

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

NCT0726863823 locations

NEPTUNE Match Study

NCT0457165816 locations